French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry

Ferment, Benoit; Lambert, Jérôme; Caillot, Denis; Lafon, Ingrid; Karlin, Lionel; Lazareth, Anne; Touzeau, Cyrille; Leleu, Xavier; Moya, Niels; Harel, Stéphanie; Perrot, Aurore; Bories, Pierre; Vincent, Laure; Lamure, Sylvain; Mohty, Mohamad; Malard, Florent; Manier, Salomon; Yakoub‐Agha, Ibrahim; Stoppa, Anne‐Marie; Brisou, Gabriel; Decaux, Olivier; Houot, Roch; Gouill, Steven Le; Facon, Thierry; Avet‐Loiseau, Hervé; Moreau, Philippe; Arnulf, Bertrand

doi:10.1182/blood-2022-162682

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 Similarly, a report from a French registry (n = 49 patients infused with ide-cel) noted an ORR of 76% at 3 months along with a 3-month PFS rate of 82%. 24 Hansen et al 23 also reported on the experience of 12 US institutions with commercial cilta-cel. With brief follow-up (median of 5.8 months), the observed best ORR was 89% and the 6-month PFS rate was 79%.…”

Section: Efficacymentioning

confidence: 99%

Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future

Holstein

Grant

Wildes

2023

JCO

View full text Add to dashboard Cite

Historically, the outcomes for individuals with triple-class refractory and penta-drug refractory multiple myeloma (MM) have been poor because of a dearth of effective treatment options. However, the advent of chimeric antigen receptor (CAR) T-cell and T-cell redirecting bispecific antibody (BsAb) therapies has led to unprecedented response rates and durations of response in heavily relapsed/refractory (R/R) populations. Currently, two B-cell maturation antigen (BCMA)–directed CAR T-cell therapies (idecabtagene vicleucel and ciltacabtagene autoleucel) as well as one BCMA/CD3 BsAb (teclistamab) have been approved for late-line (greater than four previous lines) R/R MM in the United States. The purpose of this review is to analyze the recent data for these approved therapies as well as provide an overview of other related CAR T-cell and BsAb therapies under development, including non–BCMA-targeting agents. We review efficacy and safety considerations, with particular focus on cytokine release syndrome, neurotoxicity, and infection risk. The relative merits and limitations of each class of therapy are discussed, as well as the areas of unmet need with respect to optimal sequencing and supportive care measures. We examine the factors that challenge equitable access to these novel therapies across minoritized racial, ethnic, and socioeconomic populations. Although it is evident that CAR T-cell and BsAb therapies will transform treatment paradigms in MM for years to come, significant work remains to identify the optimal utilization of these novel therapies and ensure equitable access.

show abstract

Section: Efficacymentioning

confidence: 99%

Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future

Holstein

Grant

Wildes

2023

JCO

View full text Add to dashboard Cite

show abstract

“…The authors found that patients with high‐risk cytogenetics, those with an ECOG PS of ≥2 at the time of lymphodepleting chemotherapy, previous exposure to BCMA‐targeted therapy (although time from this was not specified), and older age were all associated with lower PFS. A group of French investigators presented data on 53 patients who received commerically sourced ide‐cel 41 . The patients had a median age of 61 years, and although patients could receive ide‐cel after three lines of therapy, the median number of prior treatments was five, and 87% were triple‐refractory.…”

Section: Commercially Available Car‐t Products For the Treatment Of MMmentioning

confidence: 99%

“…A group of French investigators presented data on 53 patients who received commerically sourced ide-cel. 41 The patients had a median age of 61 years, and although patients could receive ide-cel after three lines of therapy, the median number of prior treatments was five, and 87% were triple-refractory. The authors reported that four patients (8%) progressed too quickly to receive idecel.…”

Section: Commercially Available Car-t Products For the Treatment Of MMmentioning

confidence: 99%

Update on the current and future use of CAR‐T to treat multiple myeloma

Gahvari,

Brunner,

Schmidt

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

Chimeric antigen receptor T‐cell (CAR‐T) therapy has become an important intervention in the management of relapsed and relapsed/refractory multiple myeloma (MM). Currently, B‐cell maturation antigen (BCMA) is the most targeted surface protein due to its ubiquitous expression on plasma cells, with increasing expression of this essential transmembrane protein on malignant plasma cells as patients develop more advanced disease. This review will explore the earliest CAR‐T trials in myeloma, discuss important issues involved in CAR‐T manufacturing and processing, as well as review current clinical trials that led to the approval of the two commercially available CAR‐T products, Idecabtagene vicleucel and ciltacabtagene autoleucel. The most recent data from trials investigating the use of CAR‐T as an earlier line of therapy will be presented. Finally, the problem of relapses after CAR‐T will be presented, including several theories as to why CAR‐T therapies fail and possible clinical caveats. The next generation of MM‐specific CAR‐T will likely include new targets such as G‐protein‐coupled receptor class C, Group 5, member D (GPRC5D) and signaling lymphocyte activation molecular Family 7 (SLAMF7). The role of CAR‐T in the treatment of MM will undoubtedly increase exponentially in the next decade.

show abstract

Cyclophosphamide/Fludarabine/Idecabtagene-vicleucel

2024

Reactions Weekly

View full text Add to dashboard Cite

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry

Cited by 6 publications

References 0 publications

Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future

Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future

Update on the current and future use of CAR‐T to treat multiple myeloma

Cyclophosphamide/Fludarabine/Idecabtagene-vicleucel

Contact Info

Product

Resources

About